Tenax Therapeutics (TENX) Stock: Buy, Sell, or Hold?
TENX - Tenax Therapeutics, Inc.
$1.93
0.04 (2.12%)
â˛
5d:
+2.12%
30d:
+7.22%
90d:
-87.52%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When TENX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TENX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TENX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: TENX is currently trading at $1.93, which is considered fair relative to its 30-day fair value range of $1.80 to $2.06.
Technical Outlook: Technically, TENX is in a strong downtrend. The price is approaching resistance at $1.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TENX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.56 (+550.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TENX is in a strong downtrend. The price is approaching resistance at $1.97. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TENX scores 30/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.56 (+550.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.80 -
$2.06
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (30/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 550.5% below Wall St target ($12.56)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.80 -
$2.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.80
Resistance Level
$1.97
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.29
Wall Street Target
$12.56
(+550.5%)
Share & Embed Analysis
Last updated: October 02, 2026 2:55 AM ET
Data refreshes hourly during market hours. Next update: 3:55 AM
Data refreshes hourly during market hours. Next update: 3:55 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TENX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$47 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
